Melike Bayram1, J A St Cyr2, William T Abraham1. 1. Cardiovascular Medicine, Ohio State University, Columbus, OH, USA. 2. Jacqmar, Inc., 10965 53rd Ave. No., Plymouth, MN 55442, USA congenital@aol.com.
Abstract
OBJECTIVES: The incidence of heart failure continues to escalate with >550,000 newly diagnosed patients annually worldwide. More than half of the patients with heart failure have preserved ejection fraction or isolated diastolic dysfunction, for which no current effective therapies for diastolic dysfunction exist. Every cell requires adequate levels of high energy phosphates to maintain integrity and function. Previous studies have demonstrated that diastolic function is energy dependent and supplemental D-ribose has shown to improve diastolic dysfunction. This study investigated what role D-ribose might play in congestive heart failure patients with preserved systolic function and diastolic dysfunction. METHODS: A total of 11 patients, New York Heart Association class II-IV, with clinical symptoms, normal left ventricular systolic function and echocardiographic evidence of diastolic dysfunction were enrolled after meeting inclusion criteria. Each patient received oral D-ribose (5 g/dose) for 6 weeks. Echocardiographic evaluation, cardiopulmonary metabolic testing and subjective questionnaire assessment were performed at baseline, 6 weeks and at 9 weeks (3 weeks after discontinuing D-ribose). RESULTS: An improvement in their tissue Doppler velocity (E'), which was maintained at 9 weeks, was demonstrated in 64% of the patients. Five patients showed an improvement in their ratio of early diastolic filling velocity (E) to early annulus relaxation velocity (E'). There was no appreciable difference in these measurements during valsalva or with leg raising and handgrip exercises. Four patients also had an improvement in their maximum predicted VO2 values; two demonstrated a worsening effect and no differences were noted in the remaining patients. Subjective assessment revealed a benefit in only one patient, worsening symptoms in one patient and no change in the remaining cohort. CONCLUSIONS: This pilot study revealed some beneficial trends with D-ribose even with this small cohort size. However, future investigations are necessary to further substantiate these observed benefits.
OBJECTIVES: The incidence of heart failure continues to escalate with >550,000 newly diagnosed patients annually worldwide. More than half of the patients with heart failure have preserved ejection fraction or isolated diastolic dysfunction, for which no current effective therapies for diastolic dysfunction exist. Every cell requires adequate levels of high energy phosphates to maintain integrity and function. Previous studies have demonstrated that diastolic function is energy dependent and supplemental D-ribose has shown to improve diastolic dysfunction. This study investigated what role D-ribose might play in congestive heart failurepatients with preserved systolic function and diastolic dysfunction. METHODS: A total of 11 patients, New York Heart Association class II-IV, with clinical symptoms, normal left ventricular systolic function and echocardiographic evidence of diastolic dysfunction were enrolled after meeting inclusion criteria. Each patient received oral D-ribose (5 g/dose) for 6 weeks. Echocardiographic evaluation, cardiopulmonary metabolic testing and subjective questionnaire assessment were performed at baseline, 6 weeks and at 9 weeks (3 weeks after discontinuing D-ribose). RESULTS: An improvement in their tissue Doppler velocity (E'), which was maintained at 9 weeks, was demonstrated in 64% of the patients. Five patients showed an improvement in their ratio of early diastolic filling velocity (E) to early annulus relaxation velocity (E'). There was no appreciable difference in these measurements during valsalva or with leg raising and handgrip exercises. Four patients also had an improvement in their maximum predicted VO2 values; two demonstrated a worsening effect and no differences were noted in the remaining patients. Subjective assessment revealed a benefit in only one patient, worsening symptoms in one patient and no change in the remaining cohort. CONCLUSIONS: This pilot study revealed some beneficial trends with D-ribose even with this small cohort size. However, future investigations are necessary to further substantiate these observed benefits.
Authors: Janet D Pierce; Qiuhua Shen; Diane E Mahoney; Faith Rahman; Kathryn J Krueger; Francisco J Diaz; Lauren Clark; Carol Smith; James Vacek; John B Hiebert Journal: Am J Cardiol Date: 2022-05-27 Impact factor: 3.133
Authors: Diane E Mahoney; John B Hiebert; Amanda Thimmesch; John T Pierce; James L Vacek; Richard L Clancy; Andrew J Sauer; Janet D Pierce Journal: Adv Biosci Clin Med Date: 2018
Authors: Janet D Pierce; Qiuhua Shen; James Vacek; Faith K Rahman; Kathryn J Krueger; Bhanu Gupta; John B Hiebert Journal: Ann Med Surg (Lond) Date: 2020-05-18
Authors: Janet D Pierce; Diane E Mahoney; John B Hiebert; Amanda R Thimmesch; Francisco J Diaz; Carol Smith; Qiuhua Shen; Dinesh Pal Mudaranthakam; Richard L Clancy Journal: BMC Cardiovasc Disord Date: 2018-04-02 Impact factor: 2.298